Glenmark gets FDA nod for skin ointment

Glenmark Pharmaceuticals has received final approval from the US health regulator USFDA ( US Food and Drug Administration) for triamcinolone acetonide ointment, used in treatment of various skin conditions.

"Glenmark Pharmaceuticals Inc, USA has been granted final approval by the USFDA for triamcinolone acetonide ointment USP, 0.5%," it said in a BSE filing.

Approval has been granted for generic version of triamcinolone acetonide ointment USP, 0.5% of Perrigo New York, Inc. This ointment is used to treat various skin conditions including eczema, dermatitis, allergies and rash.

Quoting IMS sales data for the 12 months to May, Glenmark said Triamcinolone Acetonide Ointment achieved annual sales of around $4.4 million.

The company's current portfolio consists of 116 products authorised for distribution in the US and 61 Abbreviated New Drug Application (ANDA) pending approval with the USFDA.

Shares of Glenmark Pharmaceuticals were trading 0.38% up at Rs 868.35 in the morning trade on BSE.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel